Related Experiment Videos
Treatment of dermatophytoses and pityriasis versicolor with itraconazole
Abstract:
Thirty patients (18 males and 12 females) with dermatophytoses were treated with itraconazole. Twenty-eight patients received 100 mg per day for 14 days, and two patients, one with tinea pedis and one with tinea manuum, were treated for 28 days. Thirty patients (11 males and 19 females) with pityriasis versicolor were treated with 200 mg of itraconazole. for five days. Half of the patients received the 200 mg in one dose, and the other half received 100 mg twice a day. Twenty-nine of the 30 patients with dermatophytoses were clinically and mycologically cured, and one patient was improved. All 30 patients with pityriasis versicolor experienced complete clinical and mycologic cure; no difference was noted between the two groups. Ten of the 60 patients treated reported adverse reactions to therapy. The primary adverse effects were nausea and epigastric pain; one patient had diarrhea. There were no alterations in the patients' blood biochemical values. These results suggest that itraconazole is safe and effective for the treatment of dermatomycoses.
Insights
Itraconazole effectively treated fungal infections like dermatophytoses and pityriasis versicolor in patients. The antifungal medication demonstrated high cure rates with minimal side effects, indicating its safety and efficacy.
Area of Science:
- Mycology
- Dermatology
- Pharmacology
Background:
- Fungal infections, including dermatophytoses and pityriasis versicolor, are common conditions requiring effective treatment.
- Itraconazole is a broad-spectrum antifungal agent used to manage various mycoses.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of itraconazole in treating patients with dermatophytoses and pityriasis versicolor.
- To assess the impact of different dosing regimens on treatment outcomes.
Main Methods:
- A total of 60 patients were enrolled: 30 with dermatophytoses and 30 with pityriasis versicolor.
- Dermatophytoses patients received 100 mg/day for 14 days (28 patients) or 28 days (2 patients).
- Pityriasis versicolor patients received 200 mg of itraconazole for five days, either as a single dose or divided (100 mg twice daily).
Main Results:
- Twenty-nine out of 30 patients with dermatophytoses achieved clinical and mycological cure, with one showing improvement.
- All 30 patients with pityriasis versicolor experienced complete clinical and mycological cure.
- Adverse reactions were reported by 10 out of 60 patients, primarily nausea and epigastric pain; no significant biochemical alterations were observed.
Conclusions:
- Itraconazole is a safe and highly effective treatment for dermatophytoses and pityriasis versicolor.
- The study supports the use of itraconazole for managing common superficial fungal infections.
- Minimal adverse effects and lack of biochemical changes suggest a favorable safety profile.